{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:34:13Z","timestamp":1788449653530,"version":"build-2803163510"},"reference-count":13,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2021,9,17]]},"abstract":"<jats:p>It has been postulated that the injectable solution formulation of remdesivir could be more nephrotoxic than the lyophilized powder since it contains twice as much sulfobutylether-\u03b2-cyclodextrin (SBECD). Therefore, we evaluated 1,000 hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who received remdesivir lyophilized powder or solution.<\/jats:p>","DOI":"10.1128\/aac.01045-21","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T18:23:55Z","timestamp":1627323835000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":11,"title":["Renal and Hepatic Toxicity Analysis of Remdesivir Formulations: Does What Is on the Inside Really Count?"],"prefix":"10.1128","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8873-1451","authenticated-orcid":true,"given":"Sunish","family":"Shah","sequence":"first","affiliation":[{"name":"Yale New Haven Health System, Department of Pharmacy Services, New Haven, Connecticut, USA"},{"name":"University of Pittsburgh Medical Center, Antimicrobial Management Program, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler W.","family":"Ackley","sequence":"additional","affiliation":[{"name":"Yale New Haven Health System, Department of Pharmacy Services, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey E.","family":"Topal","sequence":"additional","affiliation":[{"name":"Yale New Haven Health System, Department of Pharmacy Services, New Haven, Connecticut, USA"},{"name":"Yale University School of Medicine, Department of Internal Medicine, Section of Infectious Diseases, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"Johns Hopkins University and Medicine. 2020. COVID-19 map. Johns Hopkins Coronavirus Resource Centre. https:\/\/coronavirus.jhu.edu\/map.html. Accessed 15 November 2020."},{"key":"e_1_3_2_3_2","unstructured":"COVID-19 Treatment Guidelines Panel. 2020. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. https:\/\/www.covid19treatmentguidelines.nih.gov\/. Accessed 2 May 2021."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3379"},{"key":"e_1_3_2_6_2","volume-title":"Remdesivir (Veklury) [package insert].","author":"Gilead","year":"2020","unstructured":"Gilead. 2020. Remdesivir (Veklury) [package insert]. Gilead, Foster City, CA."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.22109"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1851"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02290-20"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020121692"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc2872"},{"key":"e_1_3_2_12_2","volume-title":"The R Project for Statistical Computing.","author":"R Core Team","year":"2016","unstructured":"R Core Team. 2016. The R Project for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. http:\/\/www.R-project.org\/."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13629"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1466"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01045-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01045-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:34:18Z","timestamp":1645486458000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01045-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,17]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,9,17]]}},"alternative-id":["10.1128\/AAC.01045-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.01045-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,17]]},"assertion":[{"value":"2021-05-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01045-21"}}